Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.

Published

Journal Article

BACKGROUND: High levels of cyclin E (CCNE) are accompanied by shorter survival in cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (CHOP)-treated diffuse large B-cell lymphomas (DLBCL), independent of the international prognostic index (IPI). Data on the prognostic role of CCNE in the 'rituximab (R)-era' are lacking. METHODS: To test reproducibility and applicability of observations from the 'pre-R era' to the 'R era', we examined the prognostic role of CCNE expression by immunohistochemistry in 1579 DLBCL on tissue microarrays (TMA); 339 patients were treated by CHOP and 635 by R-CHOP. RESULTS: 1209 samples (77%) were evaluable; failures were due to missing TMA punches and fixation artefacts. Mean expression of CCNE was 13% (0-85%); applying a cut-off of >16%, 382 DLBCL (31%) were positive. CCNE did not correlate with any of the known variables (IPI, primary site, cell of origin, proliferation, and BCL2- or C-MYC rearrangements). We were able to reproduce data suggesting an IPI- and response to therapy independent, negative prognostic impact of CCNE in CHOP-treated DLBCL patients: CCNE-positive cases had a median survival of 16 months compared with 57 months in negative ones (p=0.012). In R-CHOP-treated patients the prognostic impact of CCNE was abrogated and only IPI, cell of origin and response to therapy had a prognostic significance. CONCLUSIONS: Addition of R to CHOP overcomes the negative prognostic impact of CCNE in DLBCL. Thus, R not only prolongs survival in DLBCL but also serves a cautionary note that prognostic factors should not be transferred into the 'R era' without proper scientific studies.

Full Text

Duke Authors

Cited Authors

  • Frei, E; Visco, C; Xu-Monette, ZY; Dirnhofer, S; Dybkær, K; Orazi, A; Bhagat, G; Hsi, ED; van Krieken, JH; Ponzoni, M; Go, RS; Piris, MA; Møller, MB; Young, KH; Tzankov, A

Published Date

  • November 2013

Published In

Volume / Issue

  • 66 / 11

Start / End Page

  • 956 - 961

PubMed ID

  • 23775435

Pubmed Central ID

  • 23775435

Electronic International Standard Serial Number (EISSN)

  • 1472-4146

International Standard Serial Number (ISSN)

  • 0021-9746

Digital Object Identifier (DOI)

  • 10.1136/jclinpath-2013-201619

Language

  • eng